Lipocine's LPCN 1148 Gains Recognition in Hepatology Journal for Cirrhosis Treatment Lipocine's LPCN 1148 has been showcased in the Hepatology journal as a novel treatment targeting cirrhosis with significant implications for patients.

Lipocine's LPCN 1148 Gains Recognition in Hepatology Journal for Cirrhosis Treatment #United_States #Salt_Lake_City #Lipocine #LPCN_1148 #cirrhosis

FDA Designates Lipocine's LPCN 1148 for Fast Track Treatment of Sarcopenia in Cirrhosis Patients Lipocine Inc. has received FDA Fast Track Designation for LPCN 1148, an innovative treatment targeting sarcopenia in decompensated cirrhosis patients.

FDA Designates Lipocine's LPCN 1148 for Fast Track Treatment of Sarcopenia in Cirrhosis Patients #United_States #Salt_Lake_City #Lipocine #LPCN_1148 #Sarcopenia